Sodium Glucose Co-Transporter 2 Inhibition Following Acute Myocardial Infarction: The DAPA-MI and EMPACT-MI Trials
- PMID: 38583168
- DOI: 10.1016/j.jchf.2024.01.019
Sodium Glucose Co-Transporter 2 Inhibition Following Acute Myocardial Infarction: The DAPA-MI and EMPACT-MI Trials
Keywords: SGLT2 inhibitors; acute myocardial infarction; clinical trials; heart failure.
Conflict of interest statement
Funding Support and Author Disclosures Dr Peikert has received a research grant from the German Research Foundation. Dr Vaduganathan has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, BMS, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; and has participated on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical